Docoh
Loading...

NBIX Neurocrine Biosciences

Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.

Company profile

Ticker
NBIX
Exchange
CEO
Kevin Gorman
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
330525145

NBIX stock data

(
)

Calendar

5 May 21
13 Jun 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
19 May 21 Lyons Gary A NQSO Common Stock Grant Aquire A No No 92.35 8,833 815.73K 8,833
19 May 21 Mercier Johanna NQSO Common Stock Grant Aquire A No No 92.35 8,833 815.73K 8,833
19 May 21 Morrow George J NQSO Common Stock Grant Aquire A No No 92.35 8,833 815.73K 8,833
19 May 21 Norwalk Leslie V NQSO Common Stock Grant Aquire A No No 92.35 8,833 815.73K 8,833
19 May 21 Richard F Pops NQSO Common Stock Grant Aquire A No No 92.35 8,833 815.73K 8,833

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

99.6% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 394 392 +0.5%
Opened positions 68 63 +7.9%
Closed positions 66 74 -10.8%
Increased positions 152 139 +9.4%
Reduced positions 125 147 -15.0%
13F shares
Current Prev Q Change
Total value 20.7B 11.94B +73.4%
Total shares 94.18M 89.34M +5.4%
Total puts 517.9K 775.2K -33.2%
Total calls 610.1K 328.3K +85.8%
Total put/call ratio 0.8 2.4 -64.0%
Largest owners
Shares Value Change
BLK Blackrock 10.99M $1.07B +57.0%
JHG Janus Henderson 9.23M $897.74M +0.8%
Vanguard 8.83M $858.65M +5.9%
FMR 7.1M $690.68M -15.0%
TROW T. Rowe Price 5.77M $561.46M -7.9%
BLVGF Bellevue 3.27M $318.45M -3.6%
STT State Street 3.27M $317.75M +31.9%
BK Bank Of New York Mellon 1.93M $187.9M +64.9%
Capital International Investors 1.57M $152.74M -53.9%
Pictet Asset Management 1.56M $151.96M -7.9%
Largest transactions
Shares Bought/sold Change
BLK Blackrock 10.99M +3.99M +57.0%
Capital International Investors 1.57M -1.84M -53.9%
FMR 7.1M -1.25M -15.0%
Partner Fund Management 1.06M +1.06M NEW
Perceptive Advisors 941.83K -957.38K -50.4%
STT State Street 3.27M +790.01K +31.9%
BK Bank Of New York Mellon 1.93M +760.47K +64.9%
Deerfield Management 725K +725K NEW
Norges Bank 0 -707.4K EXIT
JPM JPMorgan Chase & Co. 1.54M +582.55K +61.1%

Financial report summary

?
Risks
  • We may not be able to continue to successfully commercialize INGREZZA, ONGENTYS, or any of our product candidates if they are approved in the future.
  • If physicians and patients do not continue to accept INGREZZA or do not accept ONGENTYS or our sales and marketing efforts are not effective, we may not generate sufficient revenue.
  • Governmental and third-party payors may impose sales and pharmaceutical pricing controls on our products or limit coverage and/or reimbursement for our products that could limit our product revenues and delay sustained profitability.
  • *Our business could be adversely affected by the effects of health pandemics or epidemics, including the COVID-19 pandemic, in regions where we or third parties on which we rely have significant sales and marketing efforts or manufacturing facilities, concentrations of clinical trial sites or other business operations, or materially affect our operations, and at our clinical trial sites, as well as the business or operations of our manufacturers, CROs or other third parties with whom we conduct business.
  • We face intense competition, and if we are unable to compete effectively, the demand for our products may be reduced.
  • Because the development of our product candidates is subject to a substantial degree of technological uncertainty, we may not succeed in developing any of our product candidates.
  • Our clinical trials may be delayed for safety or other reasons or fail to demonstrate the safety and efficacy of our product candidates, which could prevent or significantly delay their regulatory approval.
  • We depend on our current collaborators for the development and commercialization of several of our products and product candidates and may need to enter into future collaborations to develop and commercialize certain of our product candidates.
  • We may not be able to successfully commercialize ONGENTYS.
  • Use of our approved products or those of our collaborators could be associated with side effects or adverse events.
  • The limited precedent for gene therapy approvals makes it difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for the product candidates we are developing through our collaboration with Voyager.
  • We currently have no manufacturing capabilities. If third-party manufacturers of INGREZZA, ONGENTYS or any of our product candidates fail to devote sufficient time and resources to our concerns, or if their performance is substandard, our clinical trials and product introductions may be delayed, and our costs may rise.
  • We currently depend on a limited number of third-party suppliers. The loss of these suppliers, or delays or problems in the supply of INGREZZA or ONGENTYS, could materially and adversely affect our ability to successfully commercialize INGREZZA or ONGENTYS.
  • The independent clinical investigators and contract research organizations that we rely upon to conduct our clinical trials may not be diligent, careful or timely, and may make mistakes, in the conduct of our trials.
  • We do not and will not have access to all information regarding the products and product candidates we licensed to AbbVie.
  • We are subject to ongoing obligations and continued regulatory review for INGREZZA. Additionally, our other product candidates, if approved, could be subject to labeling and other post-marketing requirements and restrictions.
  • Gene therapy treatments, which we are developing pursuant to our collaboration and license agreement with Voyager, may be perceived as unsafe or may result in unforeseen adverse events. Negative public opinion and increased regulatory scrutiny of gene therapy may adversely affect our ability to initiate or continue clinical development or obtain regulatory approvals for gene therapy product candidates or the commercialization of gene therapy products.
  • If we are unable to retain and recruit qualified scientists or if any of our key senior executives discontinues his or her employment with us, it may delay our development efforts or impact our commercialization of INGREZZA, ONGENTYS or any product candidate approved by the FDA.
  • If the market opportunities for our products and product candidates are smaller than we believe they are, our revenues may be adversely affected, and our business may suffer.
  • We license some of our core technologies and drug candidates from third parties. If we default on any of our obligations under those licenses, or violate the terms of these licenses, we could lose our rights to those technologies and drug candidates or be forced to pay damages.
  • *Our indebtedness and liabilities could limit the cash flow available for our operations, expose us to risks that could adversely affect our business, financial condition and results of operations.
  • *The conditional conversion feature of the 2024 Notes, if triggered, may adversely affect our financial condition, operating results, or liquidity.
  • We have a history of losses and expect to increase our expenses for the foreseeable future, and we may not be able to sustain profitability.
  • *We have recently increased the size of our organization and will need to continue to increase the size of our organization. We may encounter difficulties with managing our growth, which could adversely affect our results of operations.
  • We may be subject to claims that we or our employees have wrongfully used or disclosed alleged trade secrets of their former employers.
  • *Because our operating results may vary significantly in future periods, our stock price may decline.
  • Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flows, financial condition or results of operations.
  • Our ability to use net operating loss carryforwards and certain other tax attributes may be limited.
  • *Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.
  • *The price of our common stock is volatile.
  • Our customers are concentrated and therefore the loss of a significant customer may harm our business.
  • *If we cannot raise additional funding, we may be unable to complete development of our product candidates or establish commercial and manufacturing capabilities in the future.
  • Compliance with changing regulation of corporate governance and public disclosure may result in additional expenses.
  • Increasing use of social media could give rise to liability and result in harm to our business.
  • *Health care reform measures and other recent legislative initiatives could adversely affect our business.
  • Any relationships with healthcare professionals, principal investigators, consultants, customers (actual and potential) and third-party payors in connection with our current and future business activities are and will continue to be subject, directly or indirectly, to federal and state healthcare laws. If we are unable to comply, or have not fully complied, with such laws, we could face penalties, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations.
  • We could face liability if a regulatory authority determines that we are promoting INGREZZA, ONGENTYS or any of our product candidates that receives regulatory approval, for “off-label” uses.
  • If we are unable to protect our intellectual property, our competitors could develop and market products based on our discoveries, which may reduce demand for our products.
  • If we fail to obtain or maintain orphan drug designation or other regulatory exclusivity for some of our product candidates, our competitive position would be harmed.
  • The technologies we use in our research as well as the drug targets we select may infringe the patents or violate the proprietary rights of third parties.
  • Our employees, independent contractors, principal investigators, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.
  • We face potential product liability exposure far in excess of our insurance coverage.
  • Our activities involve hazardous materials, and we may be liable for any resulting contamination or injuries.
  • Cyber security breaches and other disruptions could compromise our information, including the theft of our intellectual property, and could expose us to liability, which would cause our business and reputation to suffer.
  • Compliance with evolving US and global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could have a material adverse effect on our business, financial condition or results of operations.
Management Discussion
  • Product Sales, net. Net product sales were $994.1 million for 2020, $752.9 million for 2019 and $409.6 million for 2018.
  • Collaboration Revenues. Collaboration revenues reflect the achievement of certain event-based milestones, royalties earned at tiered percentage rates on any net sales of ORILISSA and ORIAHNN and license fees earned under our collaboration agreements with AbbVie and MTPC.
  • In the second quarter of 2020, we recognized a $30.0 million event-based milestone as revenue upon FDA-approval of AbbVie’s ORIAHNN for uterine fibroids. In the third quarter of 2019, we recognized a $20.0 million event-based milestone as revenue upon the FDA’s acceptance of AbbVie’s new drug application, or NDA, submission of elagolix for uterine fibroids. In the third quarter of 2018, we recognized a $40.0 million event-based milestone as revenue upon FDA-approval of AbbVie’s ORILISSA for the treatment of moderate to severe pain associated with endometriosis.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. junior Avg
New words: abandon, acetate, amisulpride, anesthesiologist, antidepressant, benzoate, Biden, brivaracetam, build, cannabidiol, carbamazepine, cenobamate, ciraprazine, citalopram, clobazam, cognitive, conference, constitutionality, diverse, divest, enable, endocrinology, endpoint, estradiol, expenditure, fluoxetine, goodwill, harbor, hospitalization, inclusion, index, indexed, infantile, infection, injunction, jeopardize, laboratory, lacosamide, lamotrigine, levetiracetam, lowest, luvadaxistat, MAA, media, member, MidCap, Ministry, mitigation, Nation, nationwide, nonpublic, norethindrone, Northern, open, opening, opt, outstanding, overturning, oxcarbazepine, perampanel, phenytoin, pimavanserin, preliminary, President, properly, reconsider, reexamining, remote, resume, roluperidone, ROU, secondary, sertraline, slowdown, social, submission, temporary, threshold, topiramate, unique, unnecessary, usability, valproate, version, video, waiver, website, Welfare, withdrew, workplace
Removed: accrue, achieved, acquiring, advance, aforementioned, amortization, augment, BBA, begin, beneficiary, biosimilar, Blueprint, calling, Camino, cancellation, cap, certiorari, classify, collected, compound, conducting, continuation, country, deemed, delinquent, deposit, digit, discretion, documented, donut, dubbed, educating, efficiently, effort, El, exercised, expensed, expiration, feedback, focused, GnRH, governed, headcount, hole, impacted, incentivize, innovative, insolvency, irrevocable, joint, life, likelihood, list, mature, monthly, motor, negotiate, negotiating, nonaccrual, obligated, ovary, permanent, permitting, perpetual, pocket, polycystic, power, presidential, proposal, published, rating, real, refractory, refund, request, revert, royalty, seeking, semiannually, sequester, Shortly, solicited, steering, Suite, supplying, syndrome, TD, terminated, unilateral